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Background: Extracellular matrix metalloproteinase inducer (Emmprin/CD147) is a transmembrane glycoprotein
that belongs to the immunoglobulin superfamily. Enriched on the surface of many tumor cells, emmprin promotes
tumor growth, invasion, metastasis and angiogenesis. We evaluated the clinical importance of emmprin and
investigated its role in endometrial cancer.
Methods: Emmprin expression was examined in uterine normal endometrium, endometrial hyperplasia and cancer
specimens by immunohistochemistry. In addition, the biological functions and inhibitory effects of an emmprin
knockdown were investigated in HEC-50B and KLE endometrial cancer cell lines.
Results: The levels of emmprin expression were significantly increased in the endometrial cancer specimens
compared with the normal endometrium and endometrial hyperplasia specimens (p< 0.05). The disease-free
survival (DFS) and overall survival (OS) rates of patients with high emmprin expression were significantly higher
than those of patients with low emmprin expression (DFS: p< 0.001; OS: p< 0.001). Emmprin knockdown by the
siRNA led to cell proliferation, migration and invasion through TGF-β, EGF, NF-κB, VEGF, MMP-2, and MMP-9
expression, which in turn resulted in increased levels of E-cadherin and reduced levels of Vimentin and Snail in
endometrial cancer.
Conclusions: The present findings suggest that low emmprin expression might be a predictor of favorable
prognosis in endometrial cancer patients, and that emmprin may represent a potential therapeutic target for
endometrial cancer.
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Potential therapeutic targetBackground
Endometrial carcinoma is the most common gynecologic
malignancy in the United States, with an estimated
43,470 new cases diagnosed in 2010 [1]. In Japan, endo-
metrial cancer is currently the fourth most common
gynecologic malignancy in women, with an estimated
incidence of 6,665 new cases in 2010 [2]. Clinical para-
meters such as the disease stage, nuclear grade, histo-
logic subtypes and tumor size are correlated with the
outcome of the disease. Therefore, it is hoped that a
better understanding of the molecular mechanism under-
lying the progression of endometrial cancer will lead to
new insights for novel therapeutic targets.
Extracellular matrix metalloproteinase inducer (Emm-
prin) is a highly glycosylated transmembrane protein that* Correspondence: k-nakamu@cc.okayama-u.ac.jp
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reproduction in any medium, provided the orbelongs to the immunoglobulin superfamily and is encoded
by a gene localized to 19p13.3. [3,4]. Most cell types show
constitutive expression of low levels of emmprin owing
to its involvement in many physiologic processes, while
high levels of emmprin expression are observed during re-
modeling processes such as inflammation, embryonic
development, wound healing and tumor progression [5-9].
Emmprin has recently been recognized as an important
modulator of tumor-stromal communication and mediates
a wide range of tumor-promoting molecular events,
including the acquisition of anchorage-independent growth
and invasive phenotype by tumor cells and tumor cell-
induced angiogenesis [10]. To date, several studies on
emmprin expression in tumor tissues have been published.
Emmprin is overexpressed in a variety of human cancers,
and its overexpression is correlated with clinically aggres-
sive behavior and poor patient survival [11-19].
The function of emmprin in malignant tumors has
been investigated in many different experimental systems.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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blasts or cancer cells to secrete increased amounts of
matrix metalloproteinases (MMPs), which are responsible
for degradation of the extracellular matrix (ECM), and
therefore facilitate tumor invasion and metastasis [4,15].
Emmprin can promote tumor cell invasion via activation
of urokinase-type plasminogen activator, nuclear factor
kappa B (NF-κB) and c-Jun N-terminal kinase (JNK) and
stimulate tumor angiogenesis via vascular endothelial cell
growth factor (VEGF), and is thus implicated in other
aspects of tumor progression, such as tumor survival and
angiogenesis [20,21].
Epithelial-mesenchymal transition (EMT) is an essential
morphologic conversion that occurs during embryonic
development. Increasing evidence suggests that a similar
process occurs during cancer progression when tumor cells
acquire the capacity to migrate, invade and metastasize
[22]. Loss of cell-cell adhesion is a prerequisite for EMT
and involves functional loss of E-cadherin. The activation
of E-cadherin repressors may be induced by signaling
mediated by growth factors, including transforming
growth factor (TGF)-β, insulin-like growth factor (IGF),
epidermal growth factor (EGF) and tumor necrosis factor
(TNF)-α, via their specific receptors [23-25]. The transcrip-
tional repressors of E-cadherin are zinc finger transcription
factors, including Snail, Slug, Smad-interacting protein 1
(SIP1) and Twist, which is also implicated in this process
[26-29]. However, it remains unclear how the mechanisms
of action of emmprin are involved in endometrial cancer
and how its roles are intertwined.
In the present study, we examined whether emmprin
expression is correlated with clinicopathological charac-
teristics in patients suffering from endometrial cancer.
The main aim of this study was to determine whether
emmprin could represent a potential therapeutic target
for endometrial cancer.
Methods
Patients and tissue specimens
Patients with normal endometrium (n = 20), endometrial
hyperplasia (n = 10) (simple, n = 1; complex, n = 2; atyp-
ical complex, n = 7), adenocarcinoma and carcinosar-
coma (n=134) were treated at Okayama University
Hospital between January 2000 and November 2009. All
of the patients underwent a total abdominal hysterectomy,
bilateral salpingo-oophorectomy and partial omentectomy
with or without pelvic and/or para-aortic lymphadenect-
omy. Pelvic lymph node dissection included the right and
left common iliac, external iliac, suprainguinal, internal
iliac, obturator, sacral and parametrial nodal chains. Para-
aortic lymph node dissection included the nodes located
from the bifurcation of the aorta to the level of the renal
vein (n=36). Adjuvant chemotherapy was used depending
the FIGO stage, grade, patient preference and physiciandiscretion. Our standard chemotherapy consisted of pacli-
taxel (175 mg/m2 infused over 3 h) and carboplatin (dosed
for an area under the curve of 5) for 3–6 cycles (n=52).
Patients with neoadjuvant chemotherapy were excluded
from this study. Tumor specimens were obtained at the
time of surgery, immediately fixed in 10% neutral-buffered
formalin and embedded in paraffin. The histological cell
types were diagnosed according to the WHO classifica-
tion, and all 134 cancer specimens were classified as
endometrioid adenocarcinomas and carcinosarcoma. The
histological grades were assigned according to the Inter-
national Federation of Gynecology and Obstetrics (FIGO)
staging classification as follows: grade 1, n=51; grade 2,
n=55; grade 3, n=22; and carcinosarcoma, n= 6) The
surgical stages were reviewed based on the FIGO staging
system as follows: stage I, n = 74; stage II, n = 11; stage III,
n = 39; stage IV, n=10. The median age at the time of sur-
gery was 57.7 years (range, 28–85). The disease-free sur-
vival (DFS) and overall survival (OS) rates were defined
as the interval between the initial operation and clinically
or radiologically proven recurrence or death, respectively.
This study was approved by the Institutional Review Board
of Okayama University Hospital.
Immunohistochemistry and staining evaluation
Formalin-fixed paraffin-embedded sections (4-μm thick-
ness) were deparaffinized with xylene and rehydrated in
ethanol. Endogenous peroxidase activity was quenched
by treatment with methanol containing 0.3% hydrogen
peroxidase for 15 min. The sections were then incubated
with an anti-emmprin antibody (Santa Cruz Biotechnology,
Santa Cruz, CA) at room temperature, followed by stain-
ing with a streptavidin-biotin -peroxidase kit (Nichirei,
Tokyo, Japan). The sections were counterstained with
hematoxylin. The levels of emmprin staining in epithelial
cells were classified into three groups by scoring the per-
centages of positive cells: 2, strong, >50% of cells stained;
1, moderate, 10–50% of cells stained; 0, weak, <10% of
cells stained. Microscopic analyses were independently
conducted by two independent examiners with no prior
knowledge of the clinical data. Final decisions in controver-
sial cases were made using a conference microscope.
Cell culture, media and small-interfering RNA
(siRNA) transfection
The HEC-50B (Japanese Collection of Research Biore-
sources (JCRB) number: JCRB1145) and KLE (ATCC
number: CRL-1622) cell lines evaluated were derived
from human endometrial cancers. The HEC-50B cell
line was maintained in Dulbecco’s modified eagle’s
medium (DMEM) (Life Technologies, Grand Island, NY)
supplemented with 10% fetal bovine serum (FBS). The
KLE cell line was maintained in DMEM/F12 medium
(Life Technologies, Grand Island, NY) supplemented
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and plated in culture dishes. At ~50% confluency, the
cells were transfected with an annealed emmprin siRNA
(sc-35298) or scramble siRNA as an empty vector for
gene silencing (final concentration, 100 nmol/L) using
a siRNA transfection reagent (sc-29528; Santa Cruz
Biotechnology). The cells were cultured with each siRNA
for 24, 48 and 72 h.
Western blotting analysis
Cell lysates were collected and estimated using a Protein
Assay system (Bio-Rad, Hercules, CA) according to the
manufacturer’s protocols. Proteins from each cell line
were subjected to SDS-PAGE, and then transferred onto
nitrocellulose membranes. The polyclonal and monoclo-
nal antibodies used for immunoblotting were as follows:
anti-emmprin, anti-NF-κB p65 and anti-NF-κB phos-
pho-p65 (p-p65) (Santa Cruz Biotechnology, Santa Cruz,
CA); and anti-β-actin (Sigma Chemical Co., St. Louis,
MO). The working dilution of all the primary anti-
bodies was 1:1000. The membranes were then incubated
with appropriate secondary antibodies. The resulting
antigen-antibody complexes were detected with an
enhanced chemiluminescence kit (Amersham Biosciences,
Piscataway, NJ).
MTS assay and cell viability assay
To evaluate the effects of emmprin on cell proliferation,
MTS and cell viability assays were performed. For the
MTS assay, cells were seeded into 96-well plates and
transfected when the cell density reached 5 × 104 cells/
well. After transfection of the cells with the emmprin
siRNA for 24, 48 and 72 h, MTS (Promega, Madison,
WI) was added for 2 h. The absorbances were measured
at 490 nm using an ELISA plate-reader (Bio-Rad Sys-
tems, Hercules, CA). The cell viability was analyzed
using SYTO 10 green fluorescent nucleic acid stain and
dead red (ethidium homodimer-2) nucleic acid stain
(Live/DeadW reduced biohazard viability/cytotoxicity kit;
Invitrogen, Eugene, OR). Briefly, cells were transfected
with the emmprin siRNA for 72 h and then incubated
with SYTO 10 green fluorescent nucleic acid stain and
dead red nucleic acid stain for 15 min. The cell fluores-
cence was observed using a fluorescence microscope
(Olympus, Tokyo, Japan).
Motility and invasion assay
To investigate the effects of the emmprin siRNA on cell
motility and invasion, we used monolayer wounding
(scratch) and chemotaxicells (polycarbonate filter, pore
size 8 μm; Kurabo, Osaka, Japan) coated with type IV
collagen. For the monolayer wounding assay, cells were
allowed to form a monolayer on a culture dish, and a
wound was made by scratching the monolayer with apipette tip. After removal of the scratched cells and
transfection with the emmprin siRNA, the cells were
cultured for 24 h. For the chemotaxicells coated with
type IV collagen, cells (1 × 105) in 100 μL of DMEM/F12
medium or DMEM supplemented with 0.1% bovine
serum albumin were placed in the upper compartment,
transfected with the emmprin siRNA and then incubated
for 72 h. After the incubation, the cells on the upper
surface of the filter were wiped off with a cotton swab.
The cells on the lower surface were stained with
hematoxylin and counted in 10 randomly selected fields.
Matrigel invasion assay
To investigate the differences in the Matrigel invasion
abilities among cells expressing emmprin, we used BD
BioCoat Matrigel Invasion Chambers (BD Bioscience,
Bedford, MA). HEC-50B and KLE cells transfected with
the emmprin siRNA were added in situ with 10 μg/mL
of DiI (Invitrogen) in DMEM/F12 or DMEM supple-
mented with 10% FBS for 1 h. Cells (5 × 104) of each
genotype were added to the inserts, and 0.75 mL of
medium was added to the bottom of each well. After
72 h of incubation, the membranes were removed from
the insert and mounted on slides, and the numbers of
invading cells were counted under a microscope. The
Matrigel assays were performed in triplicate.
Real-time and quantitative RT-PCR
Total RNA was extracted from the cell lines using an
acid guanidinium –phenol -chloroform method (ISO-
GEN; Nippon Gene, Tokyo, Japan) according to the
manufacturer's instructions. Real-time RT-PCR was per-
formed using a LightCycler rapid thermal cycler instru-
ment (Roche Diagnostics, Mannheim, Germany) under
the conditions recommended by the manufacturer. The
real-time RT-PCR used primers for emmprin, EGF and
TGF-β as previously described [30,31]. The PCR pro-
ducts were checked by melting point analyses and their
electrophoretic mobilities. Standard curves for calcula-
tion of the numbers of transcripts were created using
plasmids containing the respective amplified fragments
as inserts, and were adjusted to use glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as a reference gene.
In addition, the PCR products were analyzed by 1.5%
agarose gel electrophoresis. As an internal control,
GAPDH mRNA was also measured by quantitative RT-
PCR. The quantitative RT-PCR used primers for MMP-
2, MMP-9, VEGF, E-cadherin, Vimentin, Snail and
GAPDH as described previously [32].
Transient transfection assay
pNF-κB-responsive and pAP-1-responsive elements were
used for NF-κB and AP-1 signaling reporter assays, re-
spectively. pNF-κB-Luc and pAP-1-Luc were purchased
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were performed using Lipofectamine™ 2000 reagent (Life
Technologies). For the luciferase reporter assays, cells
were transfected with 0.5 μg of NF-κB-responsive plasmid,
AP-1-responsive plasmid, estrogen-responsive plasmid or
progesterone-responsive plasmid in combination with
0.05 μg of pTK-RLUC (Promega) as an internal control.
Their proteins were extracted using a Dual-Luciferase
reporter assay system (Promega). The firefly and Renilla
luciferase activities were measured concurrently for 12 sec
using a luminometer (LUMAT LB9507; Berthold, Wildbad,
Germany). The assays were carried out for quadruplicate
transfection experiments, and at least three independent
values were analyzed to confirm reproducibility.
Cell growth in monolayers
For evaluation of cell growth in monolayers, cells were
plated at a density of 3 × 104 cells/well in 6-well plates
containing DMEM or DMEM/F12 supplemented with
10% FBS. The cell numbers were counted in triplicate
after 1, 3, 5 and 7 days using a hemocytometer to assess
cell proliferation.
Statistical analysis
Statistical analyses were performed using the Mann–
Whitney U-test for comparisons with controls and one-Figure 1 Representative immunostaining patterns of emmprin. A) 1. W
epithelial cell staining (original magnification x100) (Grade 1 endometrioid
magnification x20). 4. Moderate epithelial cell staining (original magnificatio
epithelial cell staining (original magnification x20). 6. Strong epithelial cell s
adenocarcinoma). B) Histograms of emmprin expression according to the s
and endometrial cancer).factor ANOVA followed by Fisher's protected least sig-
nificance difference test for all pairwise comparisons.
The survival rates were calculated by the Kaplan–
Meier method, and the differences between the sur-
vival curves were examined by using the log-rank
test. The analyses were performed with the software
package StatView version 5.0 (Abacus Concepts,
Berkeley, CA). Differences were considered significant
at p< 0.05.
Results
The expression levels of emmprin were examined in
human endometrial tissues by immunostaining
Emmprin-dependent activation may have a role in con-
ventional endometrial tumorigenesis, and therefore the
emmprin activation machinery might be important. The
expression levels of emmprin were examined in human
endometrial tissues by immunostaining. Figure 1 show
representative immunostaining patterns of emmprin.
Weak epithelial staining was observed in 25 cases
(15.2%), moderate staining in 64 cases (38.9%) and
strong staining in 76 cases (45.9%). The mean scores
of the epithelial staining for emmprin were 0.85 for
normal human endometrium, 0.9 for hyperplasia and
1.42 for cancer samples. Interestingly, endometrial can-
cer had the strongest emmprin expression comparedeak epithelial cell staining (original magnification x20). 2. Weak
adenocarcinoma).3. Moderate epithelial cell staining (original
n x100) (Grade 2 endometrioid adenocarcinoma). 5. Strong
taining (original magnification x100) (Grade 3 endometrioid
pecimens (uterine normal endometrium, endometrial hyperplasia
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plasia (p< 0.05, Mann–Whitney U-test) (Figure 1C).
Table 1 shows the distribution of cases scored as posi-
tive for each of the biological parameters examined,
according to the clinicopathological characteristics in
the overall population. As expected, the expression of
emmprin had significant associations with clinicopa-
thological parameters such as FIGO stage (p= 0.009),
histology (p= 0.017), depth of myometrial invasion
(p= 0.001), cervical involvement (p= 0.001), lymph node
metastasis (p< 0.001), lymph vascular space (LVS)
involvement (p< 0.001) and peritoneal cytology (p=0.031),
whereas age and ovarian metastasis did not have significant
associations (p< 0.05, Mann–Whitney U-test). Emmprin
was most significantly associated with the DFS and OS
rates among the prognostic factors using the log-rank test
for endometrial cancer. Figure 2 shows the DFS and OSTable 1 Associations of emmprin with clinical factors in
endometrial cancer patients
Emmprin
Variable Numbers mean± SE p-value
Age (years) 0.445
<60 80 1.38 ± 0.70
≥60 54 1.48 ± 0.84
FIGO stage 0.009*
I-II 85 1.30 ± 0.65
III-IV 49 1.61 ± 0.67
Histology 0.017*
Type I (G1+G2) 106 1.34 ± 0.69
Type II (G3 + carcinosarcoma) 28 1.68 ± 0.54
Depth of myometrial invasion 0.001*
<1/2 87 1.28 ± 0.66
≥1/2 47 1.66 ± 0.63
Cervical involvement 0.001*
Negative 105 1.32 ± 0.67
Positive 29 1.75 ± 0.57
Lymph node metastasis <0.001*
Negative 116 1.34 ± 0.67
Positive 18 1.89 ± 0.47
LVS involvement <0.001*
Negative 90 1.27 ± 0.67
Positive 44 1.70 ± 0.59
Ovarian metastasis 0.127
Negative 119 1.38 ± 0.66
Positive 15 1.66 ± 0.72
Peritoneal cytology 0.031*
Negative 105 1.35 ± 0.67
Positive 29 1.65 ± 0.61
*Mann–Whitney U-test; FIGO, International Federation of Gynecology and
Obstetrics; LVS, lymph vascular space.curves of the 134 patients with endometrial cancer,
according to the emmprin expression status. The DFS and
OS rates of patients with high emmprin expression (score
2) were significantly higher than those of patients with
low emmprin expression (scores 0–1) (DFS: p< 0.001; OS:
p< 0.001). Furthermore, we examined independent prog-
nostic factor for DFS and OS of the clinicopathologic fac-
tors including stage, histology, lymph node metastasis,
deep myometrial invasion, ovarian metastasis and emm-
prin by multiple analysis. The ovarian metastasis was
strongest independent prognostic factor for DFS and OS
by multiple analysis (P=0.0245 and P=0.0222). However,
emmprin expression was not an independent prognostic
factor for DFS and OS.Protein expression, cell proliferation and cell viability
after emmprin siRNA transfection
We first examined the protein levels of emmprin
in human endometrial cancer cell lines. As shown in
Figure 3A, emmprin protein was highly expressed in
KLE, HEC-50B and Ishikawa cells, weakly expressed
in HEC-251 cells and absent in HEC-1A cells. Among
the endometrial cancer cell lines, we chose KLE and
HEC-50B endometrial cancer cells for further study.
Use of the emmprin siRNA to trigger differentiation in
endometrial cancer cells led to a time-dependent reduc-
tion in the emmprin mRNA that peaked around 72 h
(Figure 3B). The expression of emmprin protein was
significantly decreased in KLE and HEC-251 cells
after transfection with the emmprin siRNA for 72 h
(Figure 3C). The cell proliferation of HEC-50B and
KLE cells transfected with the emmprin siRNA for 72 h
was significantly inhibited as evaluated by MTS assays
(Figure 3D). The cell viabilities of HEC-50B and KLE
cells were evaluated after transfection with the emm-
prin siRNA. The percentages of viable cells were
decreased to 72.1% (HEC-50B) and 53.6% (KLE) of the
wild-type cell viabilities after 72 h of transfection with
the emmprin siRNA (Figure 3E).Motility, invasiveness and matrigel invasion after
emmprin siRNA transfection
The purpose of these experiments was to study the role
of endometrial cancers in the motility, invasiveness and
Matrigel invasion of cells transfected with the emmprin
siRNA. The cells transfected with the emmprin siRNA
were much slower than cells transfected with the wild-
type or empty vector in the motility and invasiveness
assay (Figures 4A and 4B). These findings suggest that
emmprin is associated with cell adhesion and spreading.
The percentages of cells reaching the bottom of the filter
were decreased to 61.5% and 48.9% in the Matrigel inva-
sion assay after transfection of the emmprin siRNA
Figure 2 Disease-free survival (DFS) and overall survival (OS) rates of the 134 patients with endometrial cancer according to the
emmprin expression status. Low epithelial expression, scores 0–1; high epithelial expression, score 2.
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(Figure 4C).
EMT after emmprin siRNA transfection
MMP activities have been implicated in EMT by activat-
ing growth factors and their receptors and cleaving cell-
cell and cell-ECM adhesion molecules. We examined
the transcriptional repressors of EMT families and each
growth factor. The expression of TGF-β and EGF were
decreased after transfection of the emmprin siRNA into
HEC-50B and KLE cells (Figure 5A). Loss of cell-cell
adhesion is a prerequisite for EMT and involves func-
tional loss of E-cadherin. Transfection of the emmprin
siRNA caused significant increases in the expression of
E-cadherin in HEC-50B and KLE cells. Moreover, the
expression of E-cadherin was also increased, accompan-
ied by decreased expression of Vimentin after transfec-
tion of the emmprin siRNA into HEC-50B and KLE
cells. Furthermore, the expression of Snail was signifi-
cantly decreased after transfection of the emmprin
siRNA into KLE cells (Figure 5B).
NF-κB and AP-1 signal transduction after emmprin
siRNA transfection
Emmprin can promote tumor cell invasion via activation
of NF-κB and JNK pathways. The activation of AP-1
transcriptional activity may be induced by signaling
mediated by JNK and extracellular signal-regulated kin-
ase (ERK) pathways. In the present study, we examined
the effects of the emmprin siRNA on the transcriptional
activities of NF-κB and AP-1 in HEC-50B and KLE cells.
The NF-κB transcriptional activities were decreased after
transfection of the emmprin siRNA into HEC-50B and
KLE cells. However, the AP-1 transcriptional activities
were not decreased after transfection of the emmprin
siRNA into HEC-50B and KLE cells (Figure 5C). NF-κB
p65 was not affected by transfection of the emmprin
siRNA into HEC-50B and KLE cells. However, NF-κB
p-p65 was significantly decreased after transfection of the
emmprin siRNA into KLE and HEC-251 cells (Figure 5D).NF-κB p50, JNK and ERK were not decreased after trans-
fection of the emmprin siRNA into KLE and HEC-251
cells (data not shown).
MMP-2, MMP-9 and VEGF expression after emmprin
siRNA transfection
VEGF, MMP-2 and MMP-9 are thought to be critically
involved in the processes of tumor cell migration, inva-
sion and metastasis. We examined VEGF, MMP-2 and
MMP-9 expression after transfection of the emmprin
siRNA into HEC-50B and KLE cells. Transfection of
the emmprin siRNA caused significant decreases in the
expression of MMP-2 and VEGF in HEC-50B and KLE
cells. The expression of MMP-9 was significantly
decreased by transfection of the emmprin siRNA into
KLE cells (Figure 5E).
Cell growth in monolayers
The effects of emmprin expression on cell proliferation
were analyzed after transfection of the emmprin siRNA
into the HEC-50B and KLE endometrial cancer cell
lines. We found significant inhibitory effects on cell pro-
liferation after transfection of the emmprin siRNA into
HEC-50B and KLE cells compared with transfection of
the wild-type or empty vector (p< 0.05) (Figure 5F).
Discussion
Proteins on the cell surface play important roles during
cancer progression and metastasis via their ability to
mediate cell-cell interactions and navigate the communi-
cation between cells and the microenvironment. Emm-
prin is a transmembrane glycoprotein belonging to the
immunoglobulin superfamily of molecules expressed on
the cell surface of most tumor cells. Several lines of data
have clearly shown key roles for emmprin in tumor pro-
gression and metastasis. Indeed, high levels of emmprin
have been reported in many cancers [11-19]. Accord-
ingly, emmprin expression has been found to be asso-
ciated with known risk factors for breast cancer and
with a poor prognosis of breast cancer patients [19]. In
Figure 3 Emmprin expression in endometrial cancer and real-time PCR, western blot, MTS assays and Cell viabilities of HEC-50B and
KLE cells after transfection with the emmprin siRNA. A) Western blot analysis of emmprin expression in endometrial cancer cell lines (KLE,
Ishikawa, HEC-251, HEC-1A and HEC-50B). An anti-β-actin antibody was used after transfection with the emmprin siRNA. B) Real-time PCR of
emmprin expression after transfection of the emmprin siRNA into HEC-50B and KLE cells for 24, 48 and 72 h. C) Western blot analysis of emmprin
expression after transfection of the emmprin siRNA into HEC-50B and KLE cells for 72 h. An anti-β-actin antibody was used as a loading control
in the same membrane. D) MTS assays of the cell proliferation of HEC-50B and KLE cells after transfection with the emmprin siRNA for 24, 48 and
72 h. The assays were carried out for quadruplicate transfection experiments. E) Cell viabilities of HEC-50B and KLE cells after transfection with
the emmprin siRNA for 72 h evaluated by fluorescence microscopy.
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of emmprin expression had a significant association
with recurrence [33]. However, the correlation between
emmprin expression and survival has not been studied
in endometrial cancer. In the present study, we exam-
ined whether the emmprin expression levels were asso-
ciated with uterine normal endometrium, endometrial
hyperplasia and endometrial cancer specimens. The
levels of emmprin expression were significantly increased
in the endometrial cancer specimens relative to the
normal endometrium and endometrial hyperplasia speci-
mens. Immunohistochemistry of endometrial cancer spe-
cimens from chemosensitivity patients revealed increasedemmprin expression with clinicopathological parameters
such as FIGO stage, histology, depth of myometrial inva-
sion, cervical involvement, lymph node metastasis, LVS
involvement and peritoneal cytology. Moreover, high
levels of emmprin expression were significantly asso-
ciated with the DFS and OS rates in endometrial cancer.
Interestingly, these findings indicate that low emmprin
expression might be a predictor of favorable prognosis in
endometrial cancer patients.
Glycosylated transmembrane proteins are likely to
have important roles in cellular homeostasis and their
dysregulated activities and expression have been impli-
cated in tumor development and progression. Emmprin
Figure 4 Effects on the motility and matrigel invasion of HEC-50B and KLE cells after transfection with the emmprin siRNA. A) Cell
scratch assays of HEC-50B and KLE cells after transfection with the emmprin siRNA for 24 h. B) Migration assays on type IV collagen for HEC-50B
and KLE cells after transfection with the emmprin siRNA for 72 h. C) Matrigel invasion assays after transfection of the emmprin siRNA into
HEC-50B and KLE cells for 72 h. Following the incubation, the membranes were removed from the inserts and mounted on slides. The numbers
of invading cells were counted under a microscope. The motility and Matrigel assays were performed in triplicate.
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evident by the diverse deficiencies detectable in emm-
prin knockout mice. Knockout mice deficient in the
emmprin gene are sterile and show various neurological
abnormalities. emmprin-deficient embryos are also diffi-
cult to implant. Emmprin has been found to participate
in the cell-surface orientation of monocarboxylic acid
transporters (MCTs) to the plasma membrane. Dysfunc-
tion of the retina in emmprin-deficient mice is ascribed
to the failure of plasma membrane integration of MCTs
in the tissue [5]. To date, several studies have suggested
possible roles for emmprin in the invasion of carcinoma
cells. Emmprin in tumor cells triggers the production or
release of matrix metalloproteinases in the surrounding
mesenchymal cells and tumor cells, thereby contributing
to tumor invasion. Furthermore, the association of emm-
prin with integrins might be important in signalingthrough emmprin. Engineered overexpression of emm-
prin in MDA-MB-231 human breast cancer cells stim-
ulated cell invasion but not cell proliferation [34].
Emmprin regulates cell adhesion, invasion, and cytoskel-
eton reorganization in prostate cancer cells [35]. Bladder,
prostate and gastic cancer, after transfection with emm-
prin siRNA, showed a significant inhibitory effect of cell
proliferation and invasion [36-38]. In the present study,
we found the inhibition of cell proliferation, migration
and invasion in endometrial cancer cells after transfec-
tion of the emmprin siRNA.
The activation of emmprin may be promoted by mul-
tiple mechanisms. Emmprin can also interact with key
adhesion proteins such as integrins, implying roles in
cancer cell migration and invasion. Emmprin is an
upstream inducer of several MMPs and is suggested to
be the master regulator of MMP production in disease
Figure 5 Real-time RT-PCR, quantitative RT-PCR, transient transfection assays, western blotting and cell growth of HEC-50B and KLE
cells after transfection with the emmprin siRNA. A) Real-time PCR of TGF-β and EGF expression after transfection of the emmprin siRNA
into HEC-50B and KLE cells for 72 h. B) Quantitative PCR analyses of E-cadherin, Vimentin and Snail expression levels after transfection of the
emmprin siRNA into HEC-50B and KLE cells for 72 h. GAPDH was used as a loading control. C) Transient transfection assays of NF-κB and AP-1
into HEC-50B and KLE cells after transfection with the emmprin siRNA for 72 h. The assays were carried out for quadruplicate transfection
experiments. D) Western blot analysis of NF-κB p65 and p-p65 expression after transfection of the emmprin siRNA into HEC-50B and KLE cells for
72 h. An anti-β-actin antibody was used as a loading control in the same membrane. E) PCR analyses of VEGF, MMP-2 and MMP-9 expression
levels after transfection of the emmprin siRNA into HEC-50B and KLE cells for 72 h. GAPDH was used as a loading control. F) Cell growth in
monolayers after transfection of the emmprin siRNA. The monolayer growth was evaluated for HEC-50B and KLE cells transfected with the
emmprin siRNA and cultured for 1, 3, 5 and 7 days in DMEM or DMEM/F12 medium supplemented with 10% FBS. The numbers represent the
data from triplicate experiments.
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Emmprin knockdown by the siRNA led to migration
and invasion through MMP-2, and MMP-9 expression
[38]. The inhibition by emmprin siRNA mediated migra-
tion and proliferation, which led to apoptosis by VEGFreceptor-2/VEGF system and the matrix degrading pro-
tease to block tumor cell growth and invasion in malig-
nant melanoma [39].
EMT, which has been recognized for several decades
as being critical for embryogenesis, has also recently
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http://www.biomedcentral.com/1471-2407/12/191been shown to be relevant to cancer progression. Hence,
MMP activities have been implicated in EMT by activat-
ing growth factors and their receptors and cleaving cell-
cell and cell-ECM adhesion molecules. Loss of cell-cell
adhesion is a prerequisite for EMT and involves func-
tional loss of E-cadherin. Activation of E-cadherin
repressors may be induced by signaling mediated by
growth factors, such as TGF-β, EGF, IGF and TNF-α, via
their specific receptors. The resultant signaling cascade
induces E-cadherin transcription repressors such as
Snail, Slug, SIP1 and Twist, eventually resulting in a loss
of epithelial morphology [22-29]. Emmprin/CD147 pro-
motes EMT through TGF-β signaling and is transcrip-
tionally regulated by Slug on hepatocellular carcinoma
[40]. In this study, we used RT-PCR assays to examine
whether transcriptional repressors of growth factors and
EMT family were affected in endometrial cancer cells
after transfection of the emmprin siRNA. The transfec-
tion of the emmprin siRNA caused significant increases
in the expression of E-cadherin. The activation of E-cad-
herin repressors may be induced by emmprin signaling
mediated through TGF-β and EGF. Moreover, the
expression of E-cadherin was also increased, accompan-
ied by enhanced expression of Vimentin and Snail after
transfection of the emmprin siRNA. However, IGF-1,
TNF-α, Slug, SIP1 and Twist were unaffected by trans-
fection of the emmprin siRNA (data not shown).
Emmprin can promote tumor cell invasion via activa-
tion of NF-κB, JNK, MMPs and VEGF and is thus impli-
cated in other aspects of tumor progression, such as
tumor survival and angiogenesis [20,21]. Venkatesan
et al. reported that emmprin promoted NF-κB- and AP-1-
dependent response gene activation [41]. In this study, we
investigated the mechanism of action by the emmprin
siRNA in endometrial cancer cell lines. The NF-κB tran-
scriptional activities were decreased after transfection of
the emmprin siRNA. Furthermore, NF-κB p-p65 was sig-
nificantly decreased after transfection of the emmprin
siRNA into endometrial cancer cells. However, AP-1 was
not affected by transfection of the emmprin siRNA into
endometrial cancer cells.
The functions of NF-κB in the transcription of the
mesenchymal genes encoding VEGF, Vimentin, MMP-2
and MMP-9 are critical for promoting and maintaining
a mesenchymal phenotype in cancers.
Emmprin is involved in cancer development through
its ability to stimulate MMP and VEGF production and
consequently control extracellular remodeling and anchor-
independent growth. MMP-9 and VEGF were induced via
the NF-κB pathway in an emmprin-dependent manner in
osteotropic breast cancer cells [42]. Emmprin induces
osteolysis as a direct emmprin activity as well as the
induction of release of downstream effectors, including
VEGF and MMP-9 [38]. In this study, we used RT-PCRassays to examine whether VEGF, MMP-2 and MMP-9
were affected in endometrial cancer cells after transfection
of the emmprin siRNA. The transfection of the emmprin
siRNA caused significant decreases in the expression of
VEGF, MMP-2 and MMP-9 in endometrial cancer cells.
Overall, the inhibition caused by the emmprin siRNA
affected cell proliferation, migration and invasion through
TGF-β, EGF, NF-κB, VEGF, MMP-2 and MMP-9 expres-
sion, which in turn resulted in increased levels of
E-cadherin and reduced levels of Vimentin and Snail
in endometrial cancer.
In summary, this study has revealed a critical role for
emmprin in endometrial cancer. The present findings
suggest that low emmprin expression might be a pre-
dictor of favorable prognosis in patients with endomet-
rial cancer, and that emmprin may represent a potential
therapeutic target for endometrial cancer.
Conclusions
The present study has shown that the levels of emmprin
expression were significantly increased in the endomet-
rial cancer specimens compared with the normal endo-
metrium and endometrial hyperplasia specimens. High
emmprin expression was a significant predictor for a
poor prognosis compared with low emmprin expression.
Emmprin knockdown by the siRNA led to cell prolifera-
tion, migration and invasion through TGF-β, EGF, NF-κB,
VEGF, MMP-2, and MMP-9 expression, which in turn
resulted in increased levels of E-cadherin and reduced
levels of Vimentin and Snail in endometrial cancer. Low
emmprin expression might be a predictor of favorable
prognosis in endometrial cancer patients, and that emm-
prin may represent a potential therapeutic target for endo-
metrial cancer.
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